Stocktoria
Seer, Inc. SEER
Seer, Inc. (SEER) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $16.6M at a -444.0% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.628 |
| Retained earnings / assets | -1.574 |
| EBIT / assets | -0.263 |
| Equity / liabilities | 7.051 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| SEER | Seer, Inc. | 3/9 | 4.62 | — | +17% |
| BNGO | Bionano Genomics, Inc. | 3/9 | — | — | -7.4% |
| EYPT | EyePoint, Inc. | 1/9 | -3.58 | — | -27.5% |
| ASTC | ASTROTECH Corp | 2/9 | — | — | — |
| RPID | RAPID MICRO BIOSYSTEMS, INC. | 2/9 | — | — | +19.7% |
| PRPO | Precipio, Inc. | 7/9 | -13.13 | — | +28% |
| HBIO | HARVARD BIOSCIENCE INC | 4/9 | -10.45 | — | -8.1% |
About Seer, Inc.
Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa. The company offers Proteograph Product Suite, an integrated solution, which includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company also offers Proteograph ONE, a third-generation assay; Proteograph DIRECT, which provides an automated approach for direct digestion of samples for bottom-up LC-MS proteomic analysis; and Proteograph Analysis Suite, a data analytics software suite designed to support quality control, data management, and interpretation of Proteograph output which is currently offered as a cloud-based solution. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
FAQ
Is SEER financially healthy?
Seer, Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does SEER pay a dividend?
No, Seer, Inc. does not currently pay a dividend.
How profitable is SEER?
In FY2025, Seer, Inc. had a net margin of -444.0% and a return on equity of -28.4%.
What is the analyst price target for SEER?
The average Wall-Street price target for Seer, Inc. is $4.00, about 86.9% above the recent price, from 1 analysts.
Is SEER a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Seer, Inc.: a Piotroski F-score of 3/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.